플라스미드 DNA 제조 시장 규모, 점유율과 동향 분석 보고서 : 질환별, 등급별, 용도별, 개발 단계별, 지역별, 부문 예측(2026-2033년)

Plasmid DNA Manufacturing Market Summary

The global plasmid DNA manufacturing market size was valued at USD 2.43 billion in 2025 and is projected to reach USD 9.29 billion by 2033, growing at a CAGR of 18.52% from 2026 to 2033. Growth is driven by rising demand for plasmid DNA in gene and cell therapies, mRNA vaccines, and outsourcing to specialized manufacturers.

Robust pipeline for gene therapies

The strong gene therapy pipeline drives the plasmid DNA market, as plasmid DNA is a key material for making viral vectors. As more gene therapy candidates enter the clinical trial phase for rare diseases, cancer, and heart diseases, the need for top-notch plasmid DNA is increasing, which in turn is leading producers to increase their output and to implement new technologies

The emphasis on individualized treatments is increasing the need for personalized plasmid DNA. Businesses are putting money into research to keep a steady flow of production for both clinical and commercial use, which in turn is pushing the envelope in the areas of production, purification, and GMP-compliant manufacturing and increasing the demand for viral vectors and plasmid DNA manufacturing market.

Increasing demand for plasmid DNA in various medical therapies

Rising demand for plasmid DNA in medical therapies is driving the market. Plasmid DNA is essential for mRNA vaccines, gene therapies, and cell therapies, prompting manufacturers to expand production and adopt advanced technologies.

The growing prevalence of chronic diseases, genetic disorders, and cancer is boosting plasmid DNA adoption. Companies are investing in scalable, GMP-compliant manufacturing and optimized processes to meet clinical and commercial needs, supporting market growth.

Global Plasmid DNA Manufacturing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the plasmid DNA manufacturing market on the basis of grade, development phase, application, disease, and region.

• Grade Outlook (Revenue, USD Million, 2021 - 2033)
• R&D Grade
  • Viral Vector Development
  • AAV
  • Lentivirus
  • Adenovirus
  • Retrovirus
  • Others
  • mRNA Development
  • Antibody Development
  • DNA Vaccine Development
  • Others
• GMP Grade
• Development Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Pre-Clinical Therapeutics
• Clinical Therapeutics
• Marketed Therapeutics
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• DNA Vaccines
• Cell & Gene Therapy
• Immunotherapy
• Others
• Disease Outlook (Revenue, USD Million, 2021 - 2033)
• Infectious Disease
• Cancer
• Genetic Disorder
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Grade
  • 1.2.2. Development Phase
  • 1.2.3. Application
  • 1.2.4. Disease
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
  • 1.9.1. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Increasing number of patients opting for gene therapy
  • 3.3.2. Robust pipeline for gene therapies
  • 3.3.3. Highly competitive market and various strategies undertaken by market players
  • 3.3.4. Increasing demand for plasmid DNA in various medical therapies
• 3.4. Market Restraint Analysis
  • 3.4.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy
• 3.5. Business Environment Analysis
  • 3.5.1. PESTEL Analysis
  • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Grade Business Analysis

• 4.1. Grade Segment Dashboard
• 4.2. Global Plasmid DNA Manufacturing Market Movement Analysis
• 4.3. Global Plasmid DNA Manufacturing Market Size & Trend Analysis, by Grade, 2021 to 2033 (USD Million)
• 4.4. R&D Grade
  • 4.4.1. R&D Grade Market, 2021 - 2033 (USD Million)
  • 4.4.2. Viral Vector Development
    • 4.4.2.1. Viral Vector Development Market, 2021 - 2033 (USD Million)
    • 4.4.2.2. AAV
      • 4.4.2.2.1. AAV Market, 2021 - 2033 (USD Million)
    • 4.4.2.3. Lentivirus
      • 4.4.2.3.1. Lentivirus Market, 2021 - 2033 (USD Million)
    • 4.4.2.4. Adenovirus
      • 4.4.2.4.1. Adenovirus Market, 2021 - 2033 (USD Million)
    • 4.4.2.5. Retrovirus
      • 4.4.2.5.1. Retrovirus Market, 2021 - 2033 (USD Million)
    • 4.4.2.6. Others
      • 4.4.2.6.1. Others Market, 2021 - 2033 (USD Million)
  • 4.4.3. mRNA Development
    • 4.4.3.1. mRNA Development Market, 2021 - 2033 (USD Million)
  • 4.4.4. Antibody Development
    • 4.4.4.1. Antibody Development Market, 2021 - 2033 (USD Million)
  • 4.4.5. DNA Vaccine Development
    • 4.4.5.1. DNA Vaccine Development Market, 2021 - 2033 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Others Market, 2021 - 2033 (USD Million)
• 4.5. GMP Grade
  • 4.5.1. GMP Grade Market, 2021 - 2033 (USD Million)

Chapter 5. Development Phase Business Analysis

• 5.1. Development Phase Segment Dashboard
• 5.2. Global Plasmid DNA Manufacturing Market Movement Analysis
• 5.3. Global Plasmid DNA Manufacturing Market Size & Trend Analysis, by Development Phase, 2021 to 2033 (USD Million)
• 5.4. Pre-Clinical Therapeutics
  • 5.4.1. Pre-Clinical Therapeutics Market, 2021 - 2033 (USD Million)
• 5.5. Clinical Therapeutics
  • 5.5.1. Clinical Therapeutics Market, 2021 - 2033 (USD Million)
• 5.6. Marketed Therapeutics
  • 5.6.1. Marketed Therapeutics Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global Plasmid DNA Manufacturing Market Movement Analysis
• 6.3. Global Plasmid DNA Manufacturing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 6.4. DNA Vaccines
  • 6.4.1. DNA Vaccines Market, 2021 - 2033 (USD Million)
• 6.5. Cell & Gene Therapy
  • 6.5.1. Cell & Gene Therapy Market, 2021 - 2033 (USD Million)
• 6.6. Immunotherapy
  • 6.6.1. Immunotherapy Market, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Disease Business Analysis

• 7.1. Disease Segment Dashboard
• 7.2. Global Plasmid DNA Manufacturing Market Movement Analysis
• 7.3. Global Plasmid DNA Manufacturing Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
• 7.4. Infectious Disease
  • 7.4.1. Infectious Disease Market, 2021 - 2033 (USD Million)
• 7.5. Cancer
  • 7.5.1. Cancer Market, 2021 - 2033 (USD Million)
• 7.6. Genetic Disorder
  • 7.6.1. Genetic Disorder Market, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Estimates & Trend Analysis by Grade, Development Phase, Disease, & Application

• 8.1. Regional Market Dashboard
• 8.2. Global Plasmid DNA Manufacturing Market Share By Region, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Target Disease Prevalence
    • 8.3.2.5. U.S. Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Target Disease Prevalence
    • 8.3.3.5. Canada Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Target Disease Prevalence
    • 8.3.4.5. Mexico Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Target Disease Prevalence
    • 8.4.2.5. Germany Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.4.3. UK
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Target Disease Prevalence
    • 8.4.3.5. UK Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Target Disease Prevalence
    • 8.4.4.5. France Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Target Disease Prevalence
    • 8.4.5.5. Italy Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Target Disease Prevalence
    • 8.4.6.5. Spain Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Target Disease Prevalence
    • 8.4.7.5. Denmark Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Target Disease Prevalence
    • 8.4.8.5. Sweden Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Target Disease Prevalence
    • 8.4.9.5. Norway Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Target Disease Prevalence
    • 8.5.2.5. Japan Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Target Disease Prevalence
    • 8.5.3.5. China Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Target Disease Prevalence
    • 8.5.4.5. India Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Target Disease Prevalence
    • 8.5.5.5. South Korea Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.5.6. Australia
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Target Disease Prevalence
    • 8.5.6.5. Australia Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.5.7. Thailand
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Target Disease Prevalence
    • 8.5.7.5. Thailand Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Target Disease Prevalence
    • 8.6.2.5. Brazil Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Target Disease Prevalence
    • 8.6.3.5. Argentina Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Target Disease Prevalence
    • 8.7.2.5. South Africa Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Target Disease Prevalence
    • 8.7.3.5. Saudi Arabia Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Target Disease Prevalence
    • 8.7.4.5. UAE Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Target Disease Prevalence
    • 8.7.5.5. Kuwait Plasmid DNA Manufacturing Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Categorization
• 9.2. Company Market Position Analysis, 2025
• 9.3. Participant's Overview
  • 9.3.1. Charles River Laboratories
    • 9.3.1.1. Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Danaher
    • 9.3.2.1. Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. VGXI, Inc.
    • 9.3.3.1. Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Kaneka Corp.
    • 9.3.4.1. Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Lonza
    • 9.3.5.1. Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Catalent, Inc.
    • 9.3.6.1. Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Cell and Gene Therapy Catapult
    • 9.3.7.1. Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Eurofins Genomics
    • 9.3.8.1. Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Luminous BioSciences, LLC
    • 9.3.9.1. Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Akron Biotech
    • 9.3.10.1. Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product Benchmarking
    • 9.3.10.4. Strategic Initiatives